Zai Lab Limited (HKG: 9688)

Market Cap	20.10B
Revenue (ttm)	2.76B
Net Income (ttm)	-2.10B
Shares Out	n/a
EPS (ttm)	-21.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,521,800
Open	20.50
Previous Close	20.25
Day's Range	20.15 - 20.85
52-Week Range	10.56 - 25.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia grav...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 2,175
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9688

Financial Performance

In 2023, Zai Lab's revenue was $266.72 million, an increase of 24.03% compared to the previous year's $215.04 million. Losses were -$334.62 million, -24.51% less than in 2022.

Financial numbers in USD